Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

ABSTRACT: The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer. The safety of the drug combinations will also be studied.

DISEASE(S): Advanced Cancers,Colon Cancer,Glioblastoma,Melanoma,Gastric Cancer,Advanced Solid Tumors,Prostate Cancer,Pancreatic Cancer,Breast Cancer,Neoplasms,Multiple Myeloma

PROVIDER: 2093710 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Effect of Lenalidomide on human macrophages.

Project description:Lenalidomide, an IMiD® immunomodulatory agent used for the treatment of multiple myeloma (MM),is believed to target the stromal support, but its precise mechanism on the phenotype or the effector functions of macrophages is still unclear. To investigate the effect of lenalidomide on macrophages, M-CSF generated macrophages were treated with Lenalidomide and analyzed by RNA-seq.

2021-01-23 | GSE165332 | GEO

FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

Project description:The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of a combination of dasatinib, cetuximab, and FOLFOX (5-fluorouracil [5-FU], leucovorin [LV], and Eloxatin [oxaliplatin]) that can be given to patients with metastatic colorectal cancer. The safety of these drugs in combination will also be studied. The goal of the Phase II part of this clinical research study is to learn if dasatinib given in combination with FOLFOX with or without cetuximab can help to control metastatic colorectal cancer.

| 2042092 | ecrin-mdr-crc

Expression data of human NK cell treated with lenalidomide

Project description:Lenalidomide, an analogue of thalidomide, is immuno-modulatory drug and has been used for many types of cancer therapy. Recently, it has been reported that lenalidomide can enhance the function of NK cell during IL-2 response. However, molecular mechanism of action of lenalidomide in NK cells is unclear still. To investigate the modification by lenalidomide on NK cells, we conducted the analysis of gene expression on NK cells.

2022-10-14 | GSE138850 | GEO

CC-122 versus Lenalidomide

Project description:CC-122 versus Lenalidomide

| PRJNA474537 | ENA

Identification of Lenalidomide resistance pathways in Myeloma and targeted re-sensitization using Cereblon replacement, inhibition of STAT3 or targeting of IRF4

Project description:In the present study, we established four lenalidomide resistant HMCLs by culturing IMiD responsive HMCLs in the presence of lenalidomide for an extended time. Those resistant cell lines were studied along with their isogenic-sensitive lines to identify the genetic pathways underlying changes associated with resistance. Here mRNAseq was performed to detect the gene expression changes in XG1LenRes compared with its IMiDs sensitive parental cell line XG1.

2019-12-07 | GSE123506 | GEO

Development of gene expression signatures for lenalidomide treatement on megakaryocyte

Project description:To clarify the machinery how lenalidomide inhibit proplatelet formation of megakaryocytes, we performed transcriptome analysis of megakaryocytes derived from human hematopoietic stem/progenitor cells in the liquid culture system with or without lenalidomide. Differentially expressed genes were comprehensively evaluated by gene set enrichment analysis. Untreated megakaryocytes showed the estradiol-responded gene expression signatures, whereas the lenalidomide-treated megakaryocytes did not. Furthermore, we performed a rescue strategy with exogenous estradiol, confirming that lenalidomide-induced inhibition of proplatelet formation should be due to the deficiency of endogenous estradiol action in megakaryocytes.

2018-06-30 | GSE111994 | GEO

CC-122 versus Lenalidomide

Project description:Gene expression profiles of OSU-CLL cells were tested after exposure to CC-122 (0.1 and 1 micromolar), Lenalidomide (1 micromolar), or DMSO, at 5 and 24 hours

2021-06-04 | GSE115328 | GEO

Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide [aCGH]

Project description:The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their anti-tumor effects remains unclear. We investigated the role of cereblon (CRBN), a primary teratogenic target of thalidomide, in the anti-myeloma activity of IMiDs. CRBN depletion is initially cytotoxic to human myeloma cells but surviving cells with stable CRBN depletion become highly resistant to both lenalidomide and pomalidomide, but not to the unrelated drugs bortezomib, dexamethasone and melphalan. Acquired deletion of CRBN was found to be the primary genetic event differentiating isogenic MM1.S cell lines cultured to be sensitive or resistant to lenalidomide and pomalidomide. Gene expression changes induced by lenalidomide were dramatically suppressed in the presence of CRBN depletion further demonstrating that CRBN is required for lenalidomide activity. Downstream targets of CRBN include interferon regulatory factor 4 (IRF4) previously reported to also be a target of lenalidomide. Patients exposed to and putatively resistant to lenalidomide had lower CRBN levels in paired samples before and after therapy. In summary, CRBN is an essential requirement for IMiD activity, and a possible biomarker for the clinical assessment of anti-myeloma efficacy. We included two isogenic MM1.S cell lines, which differ in the sensibiligy to lenalidomide. We included MM1.S and MM1.S res, which were sensitive and resistant to lenalidomide, respectively.

2011-09-30 | E-GEOD-31451 | biostudies-arrayexpress

Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide [expression profiling]

2011-09-30 | E-GEOD-31421 | biostudies-arrayexpress

Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide

Project description:This SuperSeries is composed of the following subset Series: GSE31421: Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide [expression profiling] GSE31451: Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide [aCGH] Refer to individual Series

2011-09-30 | E-GEOD-31452 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data